Low Earth Orbit
From Space to Sight: Leveraging Microgravity to Enhance Artificial Retina Technology
Nicole Wagner, Ph.D.
LambdaVision
PAO-04-25-CL-02Apr 4, 2025
Ophthalmology
The Shift from Early- to Late-Phase Ophthalmology Retina Market in 2024: Proactive Planning for Late-Stage Clinical Success
Jennifer Christiansen, Ph.D.; Tracey Roberts, MSHS; Debra Schaumberg, Sc.D., O.D., M.P.H.
PPD clinical research business of Thermo Fisher Scientific
PAO-08-24-CL-05Sep 16, 2024
Retinal Disease
Pioneering Breakthroughs in Retinal Disease Treatment
David Alvaro, Ph.D.; David Esposito; David Zacks, M.D., Ph.D.
Pharma's Almanac
PAO-12-23-CL-01Dec 14, 2023
Ophthalmic
Transformative Early and Patient-Centric Treatments for Retinal Diseases
David Alvaro, Ph.D.; Kerrie Brady
Pharma's Almanac
PAO-05-022-CL-06May 17, 2022
Global License Agreement
Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program
Hovione
PR-M05-22-04May 9, 2022
Regulatory Compliance
Addressing Regulatory Challenges for Ophthalmic Combination Products
Jeff Tremain; Ania VanDyke
AbbVie Contract Manufacturing
PAO-04-022-CL-09Apr 28, 2022
Aseptic Processing
Unique Manufacturing Challenges Associated with Sterile Eye Ointments
Tim Schuetter
AbbVie Contract Manufacturing
PAO-04-022-CL-04Apr 19, 2022
Ophthalmology
On the Future of Ocular Therapies
Roca Therapeutics
PAO-04-22-R221-63Apr 29, 2021
Ophthalmology
Hovione Completes its Phase II Clinical Trial of the First Minocycline Ophthalmic Showing Promise in Dry Eye Disease Associated with Inflamed Meibomian Gland Dysfunction
Hovione
PR-M03-21-003Mar 17, 2021
Ophthalmic Formulation
Targeting Retinal Diseases with an Ophthalmic Formulation of Bevacizumab
Larry Kenyon
Outlook Therapeutics
PAP-Q4-20-CL-018Dec 9, 2020
Ophthalmology
Tackling Genetic Eye Diseases with Novel RNA Therapies
Daniel A. de Boer
ProQR Therapeutics
PAP-Q4-19-CL-027Dec 6, 2019
Ophthalmology
Innovative Therapies to Treat Rare and Underserved Eye Diseases
Shankar Musunuri, Ph.D.
Ocugen
PAP-Q4-19-CL-025Dec 6, 2019
Global Network
Applying an Established and Continuously Upgraded Global Network for CDMO Services
Lorraine Hill
Aspen Pharma
PAP-Q3-19-CL-002-2034Oct 28, 2019
Recall
Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products
Nice Insight
PR-M07-19-NI-036Jul 15, 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Aldeyra Therapeutics
PR-M01-19-NI-096Feb 1, 2019